ロード中...
A Pilot Study of Bevacizumab and Interferon-α2b in Ocular Melanoma
OBJECTIVES: We hypothesized that administration of bevacizumab, a monoclonal antibody that neutralizes vascular endothelial growth factor, in combination with high-dose interferon-alpha2b (IFN-α2b), an inhibitor of basic fibroblast growth factor, would have clinical activity in patients with metasta...
保存先:
| 出版年: | Am J Clin Oncol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4294796/ https://ncbi.nlm.nih.gov/pubmed/20458209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3181d2ed67 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|